Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalnicastobart (LVGN7409) Monotherapy in Advanced Malignancies
NCT05152212Phase 1Completed
- Sponsor
- Lijin Biomedical Technology
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVGN7409 in solid tumor and lymphoma, sponsored by Lijin Biomedical Technology. Primary endpoints: Maximum Tolerated Dose / Recommended Dose for Expansion / Recommended Phase 2 Dose up to 24 months, Incidence rate of Dose-limiting Toxicity at 3 weeks and 1 more. Started Sep 2021; status: completed.
02
Drugs
LVGN7409
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05152212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152212.